Entero Therapeutics, Inc. (ENTO)
Entero Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boca Raton, FL, US. The stock last traded at $2.85, down 5.00% on the session, giving a market capitalisation of $13.6M. On trailing twelve-month figures it carries a trailing P/E of -0.44, a net margin of -4961.9%. Its beta of 1.19 implies it has historically moved more than the broad market.
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company formerly known as First Wave BioPharma, Inc. (and prior to September 2021, AzurRx BioPharma, Inc.), is dedicated to discovering and advancing localized, non-systemic treatments for various gastrointestinal conditions. Its development pipeline features several key therapeutic candidates: latiglutenase, an oral biotherapeutic formulated to break down gluten into non-immunogenic peptides for celiac disease patients; adrulipase, a recombinant lipase enzyme engineered to facilitate the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist aimed at addressing gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for individuals with inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Furthermore, the company is developing CypCel, a management tool designed to monitor the intestinal health of recovering celiac disease patients. Founded in 2014, the company's operations are based in Boca Raton, Florida.
Entero Therapeutics, Inc. is most often compared with the following Healthcare names: